TEHRAN – The food and drug administration issued an emergency use license for two domestic vaccines of “Razi Cov Pars” and “Fakhra”, IRNA reported on Monday.

Developed by the Razi Vaccine and Serum Research Institute, Razi Cov Pars is the second Iranian-made vaccine that started the clinical trial on February 27.

The vaccine is protein-based, which employs recombinant versions of the spike protein and tutors the immune system against the virus by producing antibodies.

It is developed in 3 doses. The first two doses are injectable and the third dose is intranasal. The second dose of the vaccine will be injected into the volunteers 21 days later and the third dose will be inhaled 51 days later.

Fakhra vaccine, the third domestically-developed COVID-19 vaccine, named after nuclear scientist Mohsen Fakhrizadeh, who was assassinated in November last year near Tehran, was unveiled and started the clinical trial on March 16.

Homegrown vaccines
According to the Food and Drug Administration, 14 vaccines are being domestically developed in the country which are in different study phases.

Made by researchers at the Headquarters for Executing the Order of the Imam, COVIRAN BAREKAT was the first domestic vaccine that was unveiled on December 29, 2020, and received the license for public use on June 14.

Pastu Covac, developed jointly by the Pasteur Institute of Iran and Cuba's Finlay Vaccine Institute, is another homegrown vaccine, which has received the emergency use license, after COVIRAN.

FB/MG